AELIS.PA stock jumps 13.99% intraday to €2.20 on heavy 493,545 volume: what traders should watch next
AELIS.PA stock is the top high-volume mover on EURONEXT intraday after jumping 13.99% to €2.20 on 493,545.00 shares traded. The move follows a large spike in relative volume (relVolume 12.84) and pushes the price well above the 50-day average of €1.15. Traders are reacting to clinical progress signals and sector flows in European healthcare. We examine why volume matters now, how fundamentals and technicals line up, and what the Meyka AI model and market metrics say for short-term and medium-term scenarios.
Intraday price action and volume drivers for AELIS.PA stock
The main intraday fact is heavy trading: AELIS.PA stock rose from an open of €2.10 to a high of €2.30 with volume 493,545.00, well above the average 38,063.00. High relative volume signals active repositioning by traders and potential headline follow-through. Day low was €1.96, previous close €1.93, and the immediate range shows strong buying interest through the morning session.
Fundamentals and valuation snapshot for Aelis Farma SA (AELIS.PA)
Aelis Farma SA trades on EURONEXT in Europe with market cap €29,990,932.00 and shares outstanding 13,632,242.00. Trailing EPS is -0.60 and PE is -3.67, reflecting losses as the biotech advances clinical programs. Key ratios: PB 4.92, Price/Sales 12.86, current ratio 3.18. These figures mark AELIS.PA stock as a high-risk, research-driven biotech with meaningful cash per share of €0.79.
Meyka AI rates AELIS.PA with a score out of 100 and technical indicators
Meyka AI rates AELIS.PA with a score out of 100: 60.80 / 100 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Technicals show RSI 59.40, MACD histogram 0.01, and CCI 117.62, indicating bullish momentum but no strong trend (ADX 17.53). On balance, volume and momentum support short-term strength while fundamentals argue for caution.
Catalysts, risks and news flow affecting AELIS.PA stock
Key catalysts include Phase 2b progress for AEF0117 and any clinical updates or partner announcements. Risks are trial setbacks, cash burn and debt metrics (debt/equity 1.13). Investors should monitor upcoming earnings announcement scheduled 2026-03-30 and sector moves in healthcare. For context on comparisons and wider market coverage see industry summaries on Investing.com and Seeking Alpha source source.
Short-term trading levels and price targets for AELIS.PA stock
Important intraday supports are €1.96 (day low) and prior close €1.93; initial resistance is today’s high €2.30 and the next structural level is the 52-week mid-range near €5.10. We set scenario price targets: conservative €1.66, base €2.80, bullish €7.17, depending on clinical news and market appetite. Traders should use tight risk controls given the stock’s volatility and low market cap.
Liquidity, sector context and portfolio considerations
AELIS.PA stock shows a surge in liquidity today but average daily volume is modest at 38,063.00, making intraday moves easier and longer term exits harder. The company sits in the biotech segment of the Healthcare sector, which has lagged larger pharma but benefits from targeted clinical successes. For portfolio managers, AELIS.PA is a small-cap speculative biotech allocation, suitable only as a minor percentage of risk capital.
Final Thoughts
Key takeaways: AELIS.PA stock is moving on clearly elevated intraday volume and positive momentum, trading €2.20 intraday after a 13.99% jump on 493,545.00 shares. Meyka AI’s forecast model projects a short-term scenario at €1.66 (implied downside -24.55% from today) and a quarterly scenario at €7.17 (implied upside 225.95%). These are model-based projections and not guarantees. Our blended view: the Meyka grade (B, score 60.80) supports a cautious HOLD — technicals favour short-term trades while fundamentals and cash runway keep long-term risk elevated. Traders focused on high-volume movers can use intraday support at €1.96 and resistance at €2.30, with stop placement that limits losses to a pre-defined share of capital. Watch clinical updates and the earnings date on 2026-03-30; any positive trial news could validate the bullish scenario, while negative results would likely re-test the year low €0.67. Meyka AI provides this as an AI-powered market analysis platform; forecasts are projections and not investment advice.
FAQs
Why did AELIS.PA stock spike today?
The intraday spike to €2.20 was driven by heavy volume (493,545.00) and momentum trading. Market participants are pricing clinical progress and sector flows. No single official release explains all volume; monitor company and trial announcements.
What valuation metrics should I watch for AELIS.PA stock?
Focus on EPS -0.60, PE -3.67 (loss-making), PB 4.92, cash per share €0.79, and current ratio 3.18. For biotechs, cash runway and trial milestones are more relevant than standard profit metrics.
What price targets and scenarios apply to AELIS.PA stock?
Meyka AI gives a conservative target €1.66, base €2.80, and bullish €7.17. These reflect different clinical and market outcomes and are model projections, not guarantees.
Should I trade AELIS.PA stock on this volume move?
High intraday volume creates short-term opportunity but also risk. Use tight risk controls, position sizing, and confirm with catalyst news. The stock is speculative and best sized small in portfolios.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
